Abstract: The invention relates to a composition comprising in an aqueous phase, particles having a diameter in the range of 20 to 500 nm, said particles containing:—an oil phase;—in said oil phase,—an aqueous droplet, or—a nanocapsule (NC) comprising:—an aqueous core, and—a polymeric shell or a shell composed of an amphiphilic substance; and—a surfactant. This composition is particularly useful for encapsulating hydrophilic and/or lipophilic substances.

Abstract: A composition, an encapsulated composition and/or nanoparticles comprising at least one essential oil having a large spectrum antibacterial, antiparasitic, antifungal activity and/or a plant antipathogen, optionally at least one antibiotic and optionally a pharmaceutically acceptable carrier is disclosed. Methods for treating infectious diseases and especially bacterial, parasitic, fungal and/or plant infectious by using this composition, encapsulated composition and/or nanoparticles are also disclosed.

Abstract: The present invention relates to a melanoma antigen peptide comprising the amino acids sequence selected in the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15 or a function-conservative variant thereof. Moreover the invention also relates to a melanoma antigen peptide according to the invention for use in the prevention or the treatment of melanoma in patient.

Abstract: The present invention belongs to the field of improved personalized medicine. More precisely, the present invention relates to a method for progressively optimizing the 5-FU dose administered by continuous infusion in patients treated by a FOLFIRI regimen or a similar regimen, based on the 5-FU plasmatic concentration measured during the previous 5-FU continuous infusion and on a herein described decision algorithm. The present invention also relates to a method for treating a cancer patient in which the 5-FU dose administered in continuous infusion in each FOLFIRI or similar treatment cycle is optimized using the decision algorithm according to the invention.

Abstract: The present invention provides a new drug to treat malignant glioma, which is the most prevalent type of primary tumor of the central nervous system (CNS). The present invention indeed shows that the isolated NFL-TBS40-63 peptide is highly specific for glioma cells, in which it triggers apoptosis. It is therefore presented here for use in a method for treating malignant glioma. The present invention further relates to the use of the NFL-TBS40-63 peptide for detecting specifically glioma cells either in vivo, or in vitro, or for addressing chemical compounds to said tumor cells.

Abstract: A reversible recording medium based on optical storage of at least one item of information within a support material, includes at least one layer of support material having: base molecules able to take, in a local zone, a first collective state of molecules able to generate a first signal of second harmonic characteristic of this first collective state of molecules when excited by electromagnetic reading radiation; the base molecules having the first collective state of molecules able to transform, at least in part, into transformed molecules so as to pass to a second collective state of molecules when excited by electromagnetic writing radiation, the molecules having the second collective state of molecules able to generate a second signal of second harmonic characteristic of this second collective state of molecules when excited by the electromagnetic reading radiation. The molecules exhibit a molecular structure based on a coumarin skeleton of Formula (I).

Abstract: The invention relates to nanocapsules with a liquid lipidic core and a solid lipidic shell, the lipidic core being loaded with at least one water-soluble or water-dispersible ingredient, said ingredient being present in the form of a reverse micellar system.

Abstract: The present invention relates to a liquid lipid core/solid lipid shell capsule surface-functionalized with at least one compound containing at least one amino function, characterized in that the lipid core/lipid shell architecture is on the nanometric scale and in that said compound is covalently bonded to said solid lipid shell via a transacylation reaction. It also relates to a method for preparing such capsules.

Abstract: Provided is a method for preparing nanocapsules having a liquid lipid core and a solid shell and charged in their lipid core with at least one hydrophilic active agent involving combining microemulsions where the active agent remains in the hydrophilic phase of a first microemulsion and chill-hardening the mixture to obtain the nanocapsules charged with the hydrophilic active agent. The nanocapsules comprise the lipid core which is liquid at room temperature and the nanocapsules are encapsulated in a film which is solid at room temperature.

Abstract: The present invention relates to a method for assessing the presence and/or the severity of a lesion in an organ or tissue of a subject through automated analysis of at least one image of said organ or tissue, wherein said organ or tissue is preferably a liver organ or liver tissue, comprising the calculation of a score combining descriptors of said image, wherein said method comprises the steps of: a. measuring on said at least one image at least two descriptors of said at least one image; b. mathematically combining said at least two descriptors in a score; and c. assessing the presence and/or the severity of a lesion in the organ or tissue based on the value of the score calculated at step (b).

Abstract: The present invention relates to a melanoma antigen peptide comprising the amino acids sequence selected in the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:5 or a function-conservative variant thereof. Moreover the invention also relates to a melanoma antigen peptide according to the invention for use in the prevention or the treatment of melanoma in patient.

Abstract: An anti-glycation agent includes a Garcinia kola extract or fraction. The compositions including the extract or the fraction are used to inhibit the glycation of proteins, in particular the glycation of skin proteins involved in cutaneous aging. A method for determining the activity of compounds for inhibiting the glycation of cutaneous proteins, in particular for inhibiting the glycation of collagen is also described.

Abstract: The present invention concerns radioactive rhodium complexes, their preparation methods, and their use for the radiolabelling of biomolecules, especially monoclonal antibodies.

Abstract: The present invention relates to a melanoma antigen peptide comprising the amino acids sequence selected in the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15 or a function-conservative variant thereof. Moreover the invention also relates to a melanoma antigen peptide according to the invention for use in the prevention or the treatment of melanoma in patient.

Abstract: The invention concerns a peptide derived from intermediate filaments and an intermediate filament fragment capable of altering tubulin polymerization and used for inhibiting cell proliferation, and more particularly for obtaining medicines designed to prevent or treat diseases involving cell proliferation, such as cancers for example.

Abstract: A process for preparing nanocapsules with a liquid lipid core and a solid lipid shell, charged with at least one active agent. The process contains at least the steps of formulating a microemulsion by phase inversion of an emulsion, totally or partially forming from at least one active agent a second composition different than the microemulsion, placing the microemulsion in contact with the second composition under conditions suitable for interaction of the active agent with the microemulsion, and chill-hardening the microemulsion that has interacted with the active agent, to obtain the nanocapsules.

Abstract: There is provided (i) a method of analysing small molecules that may have a mass of <800 Da, in particular alkaloids, said method being generally referred to as MALDI-TOF-MS (or MALDI time-of-flight mass spectrometry), which is an acronym for a method of analysis by matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry. Also provided is (ii) a molecule according to formula (I) and the use of the molecule as a matrix in the analysis method.

Abstract: A measurement instrument, i.e. a mobile body, measures distances between a current position of the mobile body and obstacles in the environment of the mobile body by: a) taking at least N measurements of distances between the mobile body and the obstacles, by consecutive angular steps of A/N (A is a predetermined angular sector), and combining the distances with the respective angular steps in order to establish map data; b) moving the mobile body and repeating step a) for a new current position of the mobile body; and c) simultaneously determining, according to the distances measured for each angular step of the current position of step b) and the preceding position of step a), the current position of the mobile body in step b) on the map relative to the initial position thereof in step a), and new data of the map.

Abstract: An anti-glycation agent includes a Garcinia kola extract or fraction. The compositions including the extract or the fraction are used to inhibit the glycation of proteins, in particular the glycation of skin proteins involved in cutaneous aging. A method for determining the activity of compounds for inhibiting the glycation of cutaneous proteins, in particular for inhibiting the glycation of collagen is also described.

Abstract: The present invention relates to a method and apparatus for deconvolving a noisy measured signal obtained from a sensor device (100), said noisy measured signal (y(t)) being the sum of the convolution product (x(t)N(t)) of an input signal (x(t)) of the sensor device, representative of a feature of physical quantity, by a convolution kernel (N(t)) defined by the response function of the sensor device (100) and a noise which interfere with the measure. The method is characterized in that said method comprises an estimate computation step (400) in the course of which a minimal estimate (xmin(t)N(t)) of the convolution product of the input signal by the convolution kernel of the sensor device is computed in order that said minimal estimate stays below the noisy measured signal (y(t)) and has at least one point in common with the noisy measured signal (y(t)).